Clinical trial
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate…
NCT00500110 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00500110 |
|---|---|
| Title | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer |
| Official title | Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate |
| Enrollment | 39 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jul 12, 2007 |
| Last update posted | Apr 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: